Dr. Jeffrey Cummings
I've won the following awards
Listed, America's Top Doctors
Lifetime Achievement Award, Vegas Inc.
Honorary Doctorate, University of Wyoming
Distinuished Scientist Award, American Association of Geriatric Psychiatry
Honorary Fellow (FRCP, Hon, Thailand), Royal College of Physicians of Thailand
Rock Stars of Science, Geoffrey Beene Foundation Alzheimer's Initiative
Research Award, John Douglas French Alzheimer's Research Foundation
Ronald and Nancy Reagan Research Award, National Alzheimer's Association
Henderson Lectureship, American Geriatric Society
Sensitivity to change of composite and frequency scores of the Neuropsychiatric Inventory in mild to moderate dementia.
Int Psychogeriatr., Nov:1-8 (2012)
Oral curcumin for Alzheimer's disease: tolerability and efficacy in a 24-week randomized, double blind, placebo-controlled study.
Alzheimers Res Ther., Oct;4(5):43 (2012)
The advantages of frontotemporal degeneration drug development (partÂ 2Â of frontotemporal degeneration: The next therapeutic frontier).
Alzheimers Dement., Oct (2012)
Subgroup analysis of US and non-US patients in a global study of high-dose donepezil (23 mg) in moderate and severe Alzheimer's disease.
Am J Alzheimers Dis Other Demen., Sep;27(6):421-32 (2012)
Memory performance and fMRI signal in presymptomatic familial Alzheimer's disease.
Hum Brain Mapp., Jul (2012)
Food for Thought: SouvenaidÂ® in Mild Alzheimer's Disease.
J. Alzheimers Dis., Jul (2012)
Food for thought: Souvenaid in mild Alzheimerâ€™s disease.
J. Alzheimers Dis., 31(1):237-8 (2012)
Plasma signaling proteins in persons at genetic risk for Alzheimer disease: influence of APOE genotype.
Arch. Neurol., Jun;69(6):757-64 (2012)
Plasma methionine sulfoxide in persons with familial Alzheimer's disease mutations.
Dement Geriatr Cogn Disord., 33(4):219-25 (2012)
Estimating sample sizes for predementia Alzheimer's trials based on the Alzheimer's Disease Neuroimaging Initiative.
Neurobiol. Aging., Jan;34(1):62-72 (2013)
Animal systems in the development of treatments for Alzheimer's disease: challenges, methods, and implications.
Neurobiol. Aging., Jan;34(1):169-83 (2013)
Cerebrospinal fluid biomarkers and proximity to diagnosis in preclinical familial Alzheimer's disease.
Dement Geriatr Cogn Disord., 33(1):1-5 (2012)
Proteomic changes in cerebrospinal fluid of presymptomatic and affected persons carrying familial Alzheimer disease mutations.
Arch. Neurol., Jan;69(1):96-104 (2012)
Reviewing the role of donepezil in the treatment of Alzheimer's disease.
Curr Alzheimer Res., Sep;9(7):773-81 (2012)
Propositional density and apolipoprotein E genotype among persons at risk for familial Alzheimer's disease.
Dement Geriatr Cogn Disord., 32(3):188-92 (2011)
Alzheimer's disease clinical trials: changing the paradigm.
Curr Psychiatry Rep., Dec;13(6):437-42 (2011)
[123I]N-Ï‰-fluoropropyl-2Î²-carbomethoxy-3Î²-(4-iodophenyl)nortropane single-photon emission computed tomography brain imaging in the diagnosis of dementia with Lewy bodies.
Alzheimers Dement., Jan;8(1):74-83 (2012)
Cortical and hippocampal atrophy in patients with autosomal dominant familial Alzheimer's disease.
Dement Geriatr Cogn Disord., 32(2):118-25 (2011)
Chronic divalproex sodium use and brain atrophy in Alzheimer disease.
Neurology., Sep;77(13):1263-71 (2011)
The role of dopaminergic imaging in patients with symptoms of dopaminergic system neurodegeneration.
Brain., Nov;134(Pt 11):3146-66 (2011)